



Published in final edited form as:

*Bioorg Med Chem Lett.* 2016 March 15; 26(6): 1585–1588. doi:10.1016/j.bmcl.2016.02.005.

## Ammonium Tetrathiomolybdate as a Water-Soluble and Slow-Release Hydrogen Sulfide Donor

Shi Xu<sup>a,‡</sup>, Chun-Tao Yang<sup>b,‡</sup>, Fu-Hui Meng<sup>b</sup>, Armando Pacheco<sup>a</sup>, Li Chen<sup>b</sup>, and Ming Xian<sup>a,\*</sup>


<sup>a</sup>Department of Chemistry, Washington State University, Pullman, Washington 99164, United States

<sup>b</sup>Department of Physiology, Guangzhou Medical University, Guangzhou 511436, China

### Abstract

Ammonium tetrathiomolybdate (TTM) was found to be a slow hydrogen sulfide (H<sub>2</sub>S) releasing agent. Its H<sub>2</sub>S generation capability in aqueous solutions was confirmed by UV-vis and fluorescence assays. TTM also showed H<sub>2</sub>S-like cytoprotective effects in hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>)-induced oxidative damage in HaCaT cells.

### Graphical Abstract



### Keywords

Ammonium Tetrathiomolybdate; Hydrogen Sulfide; Donor; Oxidative damage

Hydrogen sulfide (H<sub>2</sub>S) is newly recognized as a nitric oxide (NO)-like gaseous transmitter that plays regulatory roles in many physiological and pathological processes.<sup>1–5</sup> Endogenous production of H<sub>2</sub>S involves both enzymatic pathways (mediated by cystathionine β-synthase (CBS), cystathionine γ-lyase (CSE), and 3-mercaptopyruvate sulfurtransferase (3-MST)) and non-enzymatic pathways (from the sulfane sulfur pools). Current knowledge strongly suggests that modulation of H<sub>2</sub>S could have potential therapeutic values for certain disease states, including vasodilation, anti-inflammation, anti-oxidation, and down regulation of cellular metabolism under stress.<sup>1–5</sup> Because of this, the search for compounds that can release H<sub>2</sub>S and mimic the beneficiary activities of H<sub>2</sub>S has become an attractive area in medicinal chemistry.<sup>6–10</sup> So far, a number of H<sub>2</sub>S releasing compounds (also known as H<sub>2</sub>S

\*Corresponding author: Tel.: +1-509-335-6073; fax: +1-509-335-8867; mxian@wsu.edu.

‡These authors contributed equally to this work.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

donors), such as GYY4137, dithiothiones, *N*-mercapto-based donors, persulfide-based donors, gem-dithiol-based donors, etc., have been reported (Figure 1).<sup>6–10</sup> These compounds are normally small organic molecules which can be triggered by certain biologically relevant or compatible reactions to release H<sub>2</sub>S. Some of them have shown promising bioactivities.<sup>6–10</sup> On the other hand, inorganic molecule-based donors, especially metal complexes, which can slowly hydrolyze to release H<sub>2</sub>S have not been reported. Inspired by the fact that sodium nitroprusside (SNP), with the formula Na<sub>2</sub>[Fe(CN)<sub>5</sub>NO], is a widely used NO donor,<sup>11–13</sup> we suspected that certain sulfide-containing inorganic compounds might be able to serve as interesting H<sub>2</sub>S donors in aqueous solutions. Like SNP, the release of H<sub>2</sub>S from inorganic molecule-based donors is likely to be the result of simple hydrolysis. As such, the donors would be suitable for many biological studies. Herein we wish to report the discovery of ammonium tetrathiomolybdate (TTM) as an effective inorganic H<sub>2</sub>S donor.

TTM, with the formula (NH<sub>4</sub>)<sub>2</sub>MoS<sub>4</sub>, is a commonly used building block in the chemistry of molybdenum.<sup>14,15</sup> As an excellent copper chelator, TTM has been used therapeutically in the treatment of copper toxicosis, especially for Wilson's disease.<sup>16</sup> It was previously noted that under strong acidic condition (5% H<sub>2</sub>SO<sub>4</sub>) H<sub>2</sub>S could be generated from TTM.<sup>17</sup> We first wondered if TTM could produce H<sub>2</sub>S under mild and biologically friendly conditions, especially under physiological pH. To this end, we measured H<sub>2</sub>S release from TTM in four different pH buffers (5, 6, 7.4, and 8). Normally the release of H<sub>2</sub>S from the donors can be determined by the standard methylene blue (MB) method.<sup>18</sup> However, a strong acidic condition was involved in this method. As it is known that acidic media would facilitate TTM hydrolysis, we envisioned that the standard MB method was not appropriate. In this study, a zinc-sulfide precipitation based MB method was used.<sup>19</sup> This method should avoid the false positive signals caused by acid-promoted TTM hydrolysis. Briefly, the solutions of 500 μM TTM were freshly prepared in phosphate buffers under different pH. At different time intervals, aliquots were taken to Eppendorf vials containing a mixture of zinc acetate and NaOH solution. After 15 minutes, solid ZnS was formed and collected by centrifugation. ZnS was then treated by a MB cocktail. The resulted H<sub>2</sub>S concentrations were obtained by UV-vis measurements and calculated based on a calibration curve. As shown in Figure 2, we observed immediate H<sub>2</sub>S formation in all of these TTM solutions. The level of H<sub>2</sub>S in pH 5 was significantly higher than the levels in other pH values. In all solutions we found H<sub>2</sub>S concentrations were maintained in a stable level for a long time (up to 15 hours). These results indicate TTM is a stable and slow release H<sub>2</sub>S donor.

To further confirm the production of H<sub>2</sub>S from TTM in buffers, a H<sub>2</sub>S gas trapping experiment was designed. As shown in Figure 3, a solution of TTM was placed in a sealed glass vial. An Eppendorf vial containing a solution of WSP-5, a H<sub>2</sub>S specific fluorescent probe,<sup>20</sup> was also placed in the vial to trap the evaporated H<sub>2</sub>S from the TTM solution. After incubation at 37 °C for 3 hours, the trapping solution was diluted and the fluorescence intensity (excitation at 502 nm, emission at 525 nm) was measured. Both the positive and negative controls (using the standard Na<sub>2</sub>S solution or pure buffer) were also carried out using the same procedure for comparison. As shown in Figure 4, TTM and Na<sub>2</sub>S led to significant fluorescence increases in the trapping solutions while the pure buffer did not cause any detectable fluorescence increase. The pH dependence of H<sub>2</sub>S release from TTM

was also noted as higher fluorescence was observed in pH 5 than in other pHs. These results further demonstrated H<sub>2</sub>S generation from TTM in buffers.

One of the most well-studied biological functions of H<sub>2</sub>S is its cytoprotective effects under oxidative stress. Being a H<sub>2</sub>S donor, TTM was expected to have similar effects. We then applied TTM in a cellular model of oxidative damage to study its cytoprotective ability, using protocols established in our previous works.<sup>21,22</sup> As shown in Figure 5-A, hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) alone caused the decrease of cell (HaCaT) viability due to oxidative damage. When the cells were pre-treated with TTM (50, 100, 200 μM), a dose-dependent protective effect was observed. At a higher concentration (400 μM), TTM had no protection, presumably because of the slight toxicity of TTM under high concentration. In addition, lactate dehydrogenase (LDH) release assay was also carried out to validate TTM's cytoprotective effects. As shown in Figure 5-B, the exposure of cells to H<sub>2</sub>O<sub>2</sub> (400 μM) remarkably enhanced LDH release. However, LDH release was significantly reduced when cells were pretreated with TTM (200 μM).

Mitochondria membrane potential (MMP) usually reflects whether mitochondria are healthy, which further indicates if cells are suffering from noxious damage. Rhodamine 123 (Rh123) staining followed by fluorescence photography can be used to observe MMP. Figure 6-A shows that under normal conditions the cells had bright green fluorescence. When cells were treated with H<sub>2</sub>O<sub>2</sub> (400 μM), a dramatic MMP loss was noted (Figure 6-B), evidenced by decreased fluorescence, suggesting that H<sub>2</sub>O<sub>2</sub> damaged cells. However, preconditioning with 200 μM TTM greatly impeded MMP loss by preserving mitochondrial functions (Figure 6-C). TTM alone did not significantly alter MMP (Figure 6-D). These results confirmed that TTM could exhibit H<sub>2</sub>S-like cellular protection against oxidative injury in cells.

In conclusion, our results demonstrate that ammonium tetrathiomolybdate (TTM) is an effective H<sub>2</sub>S donor in aqueous buffers. TTM's release of H<sub>2</sub>S is pH-dependent. Under neutral pH, the release is a slow but sustained process. TTM can exhibit H<sub>2</sub>S-like cytoprotection against oxidative damage. These results should promote researchers to re-think the biological activities of TTM and apply it to other studies.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.


## Acknowledgments

This work was supported by the NIH (R01HL116571) and Natural Science Foundation of Guangdong Province in China (No. 2015A030313458).


## References

1. Li L, Moore PK. *Annu Rev Pharmacol Toxicol.* 2011; 51:169. [PubMed: 21210746]
2. Fukuto JM, Carrington SJ, Tantillo DJ, Harrison JG, Ignarro LJ, Freeman BA, Chen A, Wink DA. *Chem Res Toxicol.* 2012; 25:769. [PubMed: 22263838]
3. Vandiver MS, Snyder SH. *J Mol Med.* 2012; 90:255. [PubMed: 22314625]


4. Wang R. *Physiol Rev.* 2012; 92:791. [PubMed: 22535897]
5. Kolluru GK, Shen X, Bir SC, Kevil CG. *Nitric Oxide.* 2013; 35:5. [PubMed: 23850632]
6. Zhao, Y.; Pacheco, A.; Xian, M. Medicinal chemistry: insights into the development of novel H<sub>2</sub>S donors. Part VIII. In: Moore, PK.; Whiteman, M., editors. *Chemistry, Biochemistry and Pharmacology of Hydrogen Sulfide, Handbook of Experimental Pharmacology.* Vol. 230. 2015. p. 365-388.
7. Zhao Y, Biggs TD, Xian M. *Chem Commun.* 2014; 50:11788.
8. Wallace JL. *Trends Pharmacol Sci.* 2007; 28:501. [PubMed: 17884186]
9. Kashfi K. *Antioxid Redox Signal.* 2014; 20:831. [PubMed: 23581880]
10. Wallace JL, Wang R. *Nat Rev Drug Discov.* 2015; 14:329. [PubMed: 25849904]
11. Wang PG, Xian M, Tang X, Wu X, Wen Z, Cai T, Janczuk AJ. *Chem Rev.* 2002; 102:1091. [PubMed: 11942788]
12. Butler AR, Megson IL. *Chem Rev.* 2002; 102:1155. [PubMed: 11942790]
13. Hottinger DG, Beebe DS, Kozhimannil T, Prielipp RC, Belani KG. *J Anaesth Clin Pharmacol.* 2014; 30:462.
14. Gunasundari T, Chandrasekaran S. *J Org Chem.* 2010; 75:6685. [PubMed: 20815372]
15. Prabhu KR, Devan N, Chandrasekaran S. *Synlett.* 2002; 11:1762.
16. Brewer GJ. *Matallomics.* 2009; 1:199.
17. Wang HW, Skeldon P, Thompson GE, Wood GC. *J Mater Sci.* 1997; 32:497.
18. Abdalla MA, Fogg AG, Burgess C. *Analyst.* 1982; 107:213.
19. Ang AD, Konigstorfer A, Giles GI, Bhatia M. *Adv Biol Chem.* 2012; 2:360.
20. Peng B, Chen W, Liu C, Rosser EW, Pacheco A, Zhao Y, Aguilar HC, Xian M. *Chem Eur J.* 2014; 20:1010. [PubMed: 24339269]
21. Zhao Y, Yang C, Organ C, Li Z, Bhushan S, Otsuka H, Pacheco A, Kang J, Aguilar HC, Lefer DJ, Xian M. *J Med Chem.* 2015; 58:7501. [PubMed: 26317692]
22. Park CM, Zhao Y, Zhu Z, Pacheco A, Peng B, Devarie-Baez N, Bagdon P, Zhang H, Xian M. *Mol Bio Syst.* 2013; 9:2430.




**Figure 1.**  
Representative H<sub>2</sub>S donors



**Figure 2.**  
H<sub>2</sub>S release from TTM under different pHs




**Figure 3.**  
H<sub>2</sub>S gas trapping set-up




**Figure 4.**  
H<sub>2</sub>S release of TTM detected by indirect fluorescent assay





**Figure 5.** Effects of TTM on H<sub>2</sub>O<sub>2</sub>-induced cellular damage. a) Cell viability assay under the treatment of 400 μM H<sub>2</sub>O<sub>2</sub> for 5 h in the absence or presence of various concentrations of TTM for 1h. b) LDH release assay of cells treated with 400 μM H<sub>2</sub>O<sub>2</sub> in the absence or presence of 200 μM TTM. Data were shown as the mean ± SE. \*\**P*<0.01 vs Control group, ##*P*<0.01 vs H<sub>2</sub>O<sub>2</sub> alone group.



**Figure 6.** Effects of TTM on  $\text{H}_2\text{O}_2$ -induced MMP loss in HaCaT cells. Rh123 staining followed by photofluorography for the observation of MMP. (A) Control cells, (B) Cells treated with 400  $\mu\text{M}$   $\text{H}_2\text{O}_2$  for 5h, (C) Cells treated with 400  $\mu\text{M}$   $\text{H}_2\text{O}_2$  combined with pretreatment with 200  $\mu\text{M}$  TTM for 1 h. (D) Cells treated with TTM alone. (E) Quantitative analysis of the mean fluorescence intensity (MFI) of Rh123 in group a–d using Image J software. Data were shown as the mean  $\pm$  SE. \*\* $P < 0.01$  vs Control group, \* $P < 0.05$  vs  $\text{H}_2\text{O}_2$  alone group.